Patents Examined by Kevin E. Weddington
  • Emergency devices
    Patent number: 11027072
    Abstract: Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose. Also provided herein are compositions and methods of treating opioid overdose using high dose naloxone.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: June 8, 2021
    Assignee: Adamis Pharmaceuticals Corporation
    Inventors: Mark J. Flather, Karen K. Daniels, Thomas Moll, Ronald B. Moss, Dennis J. Carlo
  • Methods of using 1-O-acetylbritannilatone spiro aryl isoxazoline compounds
    Patent number: 11028102
    Abstract: A method of inhibiting leukotriene include: administrating a therapeutically effective amount of a compound of chemical formula I or II or a pharmaceutical acceptable salt thereof to a subject, R1 is OH or OAc; X is C or N; and R2 is H, alkyl, alkoxy, benzyloxy, haloalkyl, OH, CN, NO2, or halogen, provided that when X is N, R2 is nil.
    Type: Grant
    Filed: February 29, 2020
    Date of Patent: June 8, 2021
    Assignee: XI'AN TAIKOMED PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yonghong Tang, Minghui Chang, Huafeng Qi, Chengyuan Liang, Xingke Ju, Lei Tian, Yuzhi Liu, Han Li
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases
    Patent number: 11020379
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 1, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui
  • Palmitoleic acid for use in inhibiting the attachment of sea lice to fish
    Patent number: 11020364
    Abstract: A semiochemical composition comprising a sea lice copepodits attachment inhibiting semiochemical comprising a synthesized palmitoleic acid, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof and/or mixtures thereof and an acceptable vehicle is described. Also described are methods to treat sea lice comprising administering to fish in need of such treatment a semiochemical composition comprising a sea lice attachment inhibiting semiochemical comprising a synthesized palmitoleic acid, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof and/or mixtures thereof and an acceptable vehicle.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: June 1, 2021
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Methods of inhibiting leukotriene, treating asthma and treating inflammation
    Patent number: 11001597
    Abstract: A method of inhibiting leukotriene, treating asthma, or treating inflammation includes: administrating to a subject a therapeutically effective amount of a compound of chemical formula I or II: or a pharmaceutical acceptable salt thereof. R1, R2, R3, and R4 are independently H, halogen, nitro, hydroxyl, cyano, benzyloxy, C1-C8 straight or branched alkyl, C1-C8 straight or branched haloalkyl, C1-C8 straight or branched alkoxy.
    Type: Grant
    Filed: February 29, 2020
    Date of Patent: May 11, 2021
    Assignee: XI'AN TAIKOMED PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yonghong Tang, Minghui Chang, Huafeng Qi, Chengyuan Liang, Xingke Ju
  • Method for preventing or treating autism spectrum disorders by benzoic acid salt
    Patent number: 10987327
    Abstract: A method for preventing or treating an autism spectrum disorder in a subject in need thereof may include administering to the subject a composition containing a therapeutically effective amount of a benzoic acid salt and a pharmaceutically acceptable excipient thereof. The benzoic acid salt may be administered to the subject in an amount ranging from 100 mg/day to 2000 mg/day.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 27, 2021
    Assignees: EXCELSIOR PHARMATECH LABS
    Inventors: Hsien-Yuan Lane, Pin-Chen Yang
  • Methods of treating mixed dyslipidemia
    Patent number: 10987331
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: April 27, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Dual inhibition of CDK and HSP90 destabilize H1F1 ? and synergistically induces cancer cell death
    Patent number: 10987356
    Abstract: The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: April 27, 2021
    Assignee: Institute For Cancer Research
    Inventors: Shuai Zhao, Wafik S. El-Deiry
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10987358
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 27, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Estrogen receptor ligands, compositions and methods related thereto
    Patent number: 10980767
    Abstract: Provided are compounds and methods for treating neurodegenerative diseases and conditions, such as multiple sclerosis, using an estrogen receptor-? ligand (ER? ligand).
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 20, 2021
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Rhonda R. Voskuhl
  • EP4 inhibitors and use thereof
    Patent number: 10973834
    Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: April 13, 2021
    Assignees: Arrys Therapeutics, Inc., AskAt Inc.
    Inventors: Mark Manfredi, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
  • Anti-cancer composition consisting of halofuginone and sesquiterpene lactone compounds of artemisia apiacea and use thereof
    Patent number: 10973823
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 13, 2021
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Guoqing Chen, Ruihong Gong, Dajian Yang, Aiping Lyu
  • Pharmaceutical compositions of pomalidomide
    Patent number: 10966971
    Abstract: The invention relates to pharmaceutical compositions of pomalidomide comprising pomalidomide and binder or filler at amount of at most 89% weight percent of total weight of the composition and process for the preparation of such compositions.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 6, 2021
    Assignee: Natco Pharma Limited
    Inventors: Satyanarayana Vattikuti, Krishna Murthy Bhavanasi, Naveen Krishna Yalamanchalli, Venkaiah Chowdary Nannapaneni
  • Stable pharmaceutical formulations of pemetrexed
    Patent number: 10966982
    Abstract: The present invention relates to a long term storage stable multi-dose ready-to use or ready-to dilute pharmaceutical liquid formulation comprising pemetrexed or a pharmaceutically acceptable salt thereof, an antioxidant, a preservative, a buffering agent, and a pharmaceutically acceptable fluid. The invention also relates to a process of preparing the formulation, a kit and a method of treatment of patients having lung cancer by administering the pharmaceutical formulation to a subject in need thereof.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: April 6, 2021
    Assignee: Cipla Limited
    Inventors: Sarabjit Singh, Alagumurugan Alagarswamy, Madhusudhan Malladi, Sandip Gite
  • Injectable phenol formulations and methods of their use
    Patent number: 10959962
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: March 30, 2021
    Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
  • Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
    Patent number: 10959971
    Abstract: The present disclosure relates to the use of inositol-stabilized arginine silicate complexes (“ASI”) with the addition of free inositol (“I”) to form a composition ASI+I for improving cognitive functioning in humans, particularly video game players.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: March 30, 2021
    Assignee: NUTRITION 21, LLC
    Inventor: James R. Komorowski
  • Method for treating cancer
    Patent number: 10946024
    Abstract: The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: March 16, 2021
    Assignee: Epizyme, Inc.
    Inventor: Heike Keilhack
  • Method for providing early onset of action in the treatment of rosacea
    Patent number: 10945987
    Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: March 16, 2021
    Assignee: SOL-GEL TECHNOLOGIES LTD.
    Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
  • Methods of treating mixed dyslipidemia
    Patent number: 10940131
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 9, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Method for treatment of rosacea in patients aged 65 years and older
    Patent number: 10933046
    Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: March 2, 2021
    Assignee: SOL-GEL TECHNOLOGIES, LTD.
    Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram